Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis -
5 hours ago
- #vasomotor-symptoms
- #menopause
- #non-hormonal-therapies
- Elinzanetant is a novel, dual neurokinin-targeted therapy approved for treating moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
- A network meta-analysis compared elinzanetant with other non-hormonal therapies (nHT) like paroxetine, gabapentin, fezolinetant, and desvenlafaxine.
- Elinzanetant significantly reduced daily VMS frequency compared to paroxetine, desvenlafaxine, and gabapentin.
- It also showed a greater proportion of patients achieving ≥50% reduction in VMS frequency compared to desvenlafaxine 100 mg and paroxetine.
- Elinzanetant significantly reduced VMS severity compared to desvenlafaxine 50 mg and was comparable to other treatments.
- It was more effective in reducing nighttime awakenings than paroxetine and all desvenlafaxine regimens.
- Elinzanetant improved sleep disturbance scores significantly more than fezolinetant.
- Quality of life (MENQoL) changes did not differ significantly between treatments.
- The study concludes that elinzanetant is superior or comparable to other nHT in managing VMS and improving sleep disturbances.